Immuneering (IMRX) Revenue (2020 - 2022)
Immuneering's (IMRX) quarterly Revenue came in at $455.0 in Q4 2022, down 99.76% year-on-year from $189591.0 in Q4 2021, and down 98.81% quarter-over-quarter from $38380.0 in Q3 2022.
Immuneering (IMRX) Revenue (2020 - 2022) Analysis & Trends
Immuneering's Revenue history runs 3 years deep, the most recent figure standing at $455.0 for Q4 2022.
- On a quarterly basis, Revenue fell 99.76% year-over-year to $455.0 in Q4 2022; TTM through Sep 2023 was $455.0, a 99.91% decrease from a year earlier, with the FY2022 full-year figure at $316952.0, down 84.76% from the prior year.
- Revenue eased to $455.0 in Q4 2022 per IMRX's latest filing, from $38380.0 in the prior quarter.
- Across five years, Revenue topped out at $748200.0 in Q1 2021 and bottomed at $455.0 in Q4 2022.
- The 3-year median for Revenue is $480835.0 (2020), against an average of $384127.1.
- Across the five-year window, Revenue soared 37.27% in 2021 and plunged 99.76% in 2022, its largest moves.
- Year by year, Revenue stood at $665080.0 in 2020, then slumped by 71.49% to $189591.0 in 2021, then plunged by 99.76% to $455.0 in 2022.
- Per Business Quant, the three latest IMRX Revenue figures stand at $455.0 (Q4 2022), $38380.0 (Q3 2022), and $94419.0 (Q2 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.51 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immuneering | 283.85 Mn | 283.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 455.00 |
| Sep 30, 2022 | 38,380.00 |
| Jun 30, 2022 | 94,419.00 |
| Mar 31, 2022 | 183,698.00 |
| Dec 31, 2021 | 189,591.00 |
| Sep 30, 2021 | 482,130.00 |
| Jun 30, 2021 | 660,040.00 |
| Mar 31, 2021 | 748,200.00 |
| Dec 31, 2020 | 665,080.00 |
| Sep 30, 2020 | 682,570.00 |
| Jun 30, 2020 | 480,835.00 |